•  Working Hours - Mon - Fri: 9:30 - 18:30

WMRAD

As part of the world's largest medical center, WMRAD is committed to excellence in research,
training, patient care and the advancement of the art and science of medicine.

About Image
About Logo

About Us

WMRAD

WMRAD combines financial services, regulatory affairs, investigator responsibilities, subject recruitment and retention expertise with site management so that sponsors, CROs receive excellent research services with maximum effectiveness and the best chance for positive outcomes.

OUR MISSION

Our goal is to bring the worlds latest and most advanced medicines to healthcare institutions and physicians that offer new and improved options for patients.

WHAT WE'VE ACHIEVED

WMRAD history is filled with stories of investigators, scientists and others who observed a problem and worked to solve it. The results of their accomplishments have been presented at professional meetings, documented in scientific journals and poster presentations and reported by the media.

What We Do Now

Explore Our Main Services

Service 1

Protocol/IB Review

Specialize in Phase 1- 4 clinical trials. Feasibility process is conducted with expedited review.

Service 2

Investigator Obligations

Investigators are well-trained and highly experienced according to ICH-GCP guidelines.

Service 3

Study supplies & External Vendors

We are experts in the latest technology across all vendor platforms

Service 4

Study Monitoring

We provide dedicated monitoring facilities focused on productivity, collaboration, and full access to facility to platforms.

Service 5

Site File

An up-to-date regulatory file is the core responsibility of our center’s research team.

Service 6

Facility Capabilities

Our dedicated team provides a high level of care and offers comprehensive services and advanced treatment options, all in one location.

Professional Education

Waldron Medical R&D Training Initiative (WMRAD)

The Training Initiative was established by WMRAD in 2009 upon the recommendation of Society of Clinical Research Associates charged by regulatory authorities with creating a vision for research professions education and training in Good Clinical Practices. The purpose of the Training Initiative is to provide the best education and training to all disciplines in the research field, enabling the best trial conduct. The Training Initiative will seek to support the development of a research environment that is innovative and applies the best policies and procedures to foster safety, quality, and value for the subjects.


As part of the world's largest medical center, WMRAD is committed to excellence in research, training, patient care and the advancement of the art and science of medicine. WMRAD will provide local, national and international education concentrated in areas where our clinicians and research professionals have recognized excellence and where our clinical trials have the greatest need.

Research

Research Coordinators

An essential component to becoming a world-renowned research center is the strength of medical research professionals. Since the inception of WMRAD, many of our coordinators have been able to transform their clinical research into current standards of care. Our coordinators have met many goals, those being the ability to provide quality care to patients, set the pace for competitive subject enrollment, meet worthwhile expectations to the sponsor, and enhance the caliber of the investigative site. We invite you to explore many of the clinical trials that are now in progress under WMRAD.

Online Appoinment

Make An Appointment

OUR NEWS & BLOG

Publish What You Think

Blog Image

Tempus Announces Eleven Abstracts Accepted for Presentation at the 2021 American Society of Clinical Oncology Annual Meeting

“These high impact ASCO presentations from Tempus collaborators and investigators illustrate the power of over…

Blog Image

IMFINZI and tremelimumab with chemotherapy improved progression-free survival by 28% and overall survival by 23% in 1st-line Stage IV non-small cell lung cancer vs. chemotherapy

WILMINGTON, Del.–(BUSINESS WIRE)–Positive results from the POSEIDON Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab), and tremelimumab,…

Blog Image

Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review

AUSTIN, Texas–(BUSINESS WIRE)–Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on…

-->